FOLD vs UNH

Amicus Therapeutics (FOLD) was acquired by BioMarin Pharmaceutical for $14.50 cash per share on April 27, 2026, leading to its delisting from Nasdaq on April 28, 2026. This fundamental change means FOLD no longer exists as an independent publicly traded entity. Consequently, it offers no future investment potential, let alone a '10x growth potential,' for new or existing investors, as shares are n...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...